Wedbush Maintains Neutral on Vera Therapeutics, Lowers Price Target to $34

Vera Therapeutics, Inc. Class A

Vera Therapeutics, Inc. Class A

VERA

0.00

Wedbush analyst Laura Chico maintains Vera Therapeutics (NASDAQ: VERA) with a Neutral and lowers the price target from $43 to $34.